Second Department of Internal Medicine, Osaka Medical and Pharmaceutical University Hospital, Osaka, Japan.
Endoscopic Center, Osaka Medical and Pharmaceutical University Hospital, 2-7, Daigakumachi Takatsuki, Osaka, 569-8686, Japan.
Gastric Cancer. 2022 Sep;25(5):916-926. doi: 10.1007/s10120-022-01303-y. Epub 2022 May 27.
The risk of bleeding after gastric endoscopic submucosal dissection (ESD) in antithrombotic agent users has increased, and its management remains a problem. Second-look endoscopy (SLE) following gastric ESD in antithrombotic agent users may be effective in preventing delayed bleeding, but this requires elucidation. Therefore, this study aimed to investigate the efficacy of SLE in reducing bleeding after gastric ESD in patients receiving antithrombotic agents.
This retrospective cohort study was conducted at 19 referral hospitals in Japan. A total of 1,245 patients who were receiving antithrombotic agents underwent gastric ESD between January 2013 and July 2018. The incidence of delayed bleeding was compared between SLE and non-SLE groups using propensity score matching analysis.
Overall, 858 patients (SLE group, 657 patients; non-SLE group, 201 patients) were analyzed. After matching, 198 pairs were created. Delayed bleeding occurred in 10 patients (5.1%) in the SLE group and 16 patients (8.1%) in the non-SLE group [odds ratio (OR) 0.605, 95% confidence interval (CI) 0.23-1.46, p = 0.310]. In the subgroup analysis, SLE reduced the incidence of delayed bleeding in patients receiving heparin bridging therapy (6.3% and 40.0%, respectively; p = 0.004). In the SLE group, prophylactic coagulation did not significantly reduce delayed bleeding compared to the no treatment group (14.6% and 8.6%, respectively; p = 0.140).
SLE was ineffective in reducing bleeding after gastric ESD in antithrombotic agent users, overall. A prospective comparative study is warranted to definitively evaluate the effectiveness of SLE in reducing bleeding in high-risk patients.
抗血栓药物使用者行胃内镜黏膜下剥离术(ESD)后出血风险增加,其管理仍是一个问题。抗血栓药物使用者行胃 ESD 后行二探内镜(SLE)可能有助于预防延迟性出血,但这需要进一步阐明。因此,本研究旨在探讨 SLE 降低抗血栓药物使用者胃 ESD 后出血的疗效。
这是一项在日本 19 家转诊医院进行的回顾性队列研究。2013 年 1 月至 2018 年 7 月,共有 1245 例正在接受抗血栓药物治疗的患者接受了胃 ESD。采用倾向评分匹配分析比较 SLE 组和非 SLE 组的延迟性出血发生率。
总体而言,分析了 858 例患者(SLE 组 657 例,非 SLE 组 201 例)。匹配后,共建立了 198 对。SLE 组有 10 例(5.1%)发生延迟性出血,非 SLE 组有 16 例(8.1%)[比值比(OR)0.605,95%置信区间(CI)0.23-1.46,p=0.310]。亚组分析显示,SLE 降低了肝素桥接治疗患者的延迟性出血发生率(分别为 6.3%和 40.0%,p=0.004)。SLE 组预防性凝血与无治疗组相比,并未显著降低延迟性出血的发生率(分别为 14.6%和 8.6%,p=0.140)。
总体而言,SLE 不能降低抗血栓药物使用者胃 ESD 后的出血风险。需要前瞻性的对照研究来明确 SLE 降低高危患者出血风险的效果。